ITGA4
ENSG00000115232
Target class
Membrane receptor
Chromosome
2
Approved drugs
2
Clinical candidates (approved and in development)
5
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Other names
- CD49d
- Target name
- ITGA4
- Gene name
- Integrin subunit alpha 4
- Gene symbol
- ITGA4
- Previous gene symbols
- CD49D
- Protein name
- Integrin alpha-4 (CD49 antigen-like family member D) (Integrin alpha-IV) (VLA-4 subunit alpha) (CD antigen CD49d)
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Integrin alpha subunits
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 30
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 83.08
- Tissue specificity (Gini)
- 0.752
- Tissue specificity (tau)
- 0.966
- KEGG gene identifiers
- hsa:3676
- Protein interaction confidence
- 0.82788
- Protein interaction partners
- 92
- R-HSA-198933
- R-HSA-202733
- R-HSA-216083
- R-HSA-8949275
- R-HSA-9679191
- End position
- 181538940
- Start position
- 181457202
- Chromosome
- 2
- Strand
- Forward
- Membrane
- Single-pass type I membrane protein .
- Plasma membrane
- Tissue specificity (tau)
- 0.965507
- Expression inequality (Gini)
- 0.752175
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 83.08
- Cells - Cultured fibroblasts
- 35
- Spleen
- 22.61
- Lung
- 10.29
- Small Intestine - Terminal Ileum
- 8.08
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes83.08
- Cells - Cultured fibroblasts35
- Spleen22.61
- Lung10.29
- Small Intestine - Terminal Ileum8.08
- Cervix - Endocervix6.71
- Whole Blood6.25
- Cervix - Ectocervix5.55
- Colon - Transverse3.16
- Nerve - Tibial3.06
- Brain - Cerebellum2.89
- Brain - Cerebellar Hemisphere2.73
- Adipose - Subcutaneous2.68
- Adipose - Visceral (Omentum)2.52
- Artery - Coronary2.4
- Vagina2.21
- Fallopian Tube2.19
- Colon - Sigmoid2.19
- Minor Salivary Gland2.15
- Breast - Mammary Tissue2.15
- Artery - Aorta2.1
- Thyroid1.85
- Bladder1.79
- Kidney - Medulla1.77
- Uterus1.58
And 29 more, listed on the interactive page.
- GO:0003366
- GO:0007159
- GO:0007160
- GO:0030183
- GO:0033631
- GO:0034113
- GO:0034446
- GO:0035987
- GO:0043113
- GO:0045906
- GO:0050901
- GO:1904646
- GO:1905564
- GO:2000353
- GO:0005886
- GO:0005925
- GO:0009986
- GO:0016020
- GO:0034668
- GO:0034669
- GO:0070062
- GO:0005178
- GO:0005515
- GO:0015026
- GO:0019960
- GO:0050839
Related records
Trials (226)
- A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
- A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease
- A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
- A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)
- A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
- A Multicentered Prospective Cohort Study of Chinese IBD Patients
- A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
- A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201
- A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab
- A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants
- A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants
- A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function
- A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
- A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
- A Study for Tysabri Participant Preference
- A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants
- A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
- A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
- A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis
Drugs (5)
- Abrilumab Integrin alpha-4/beta-7 inhibitor
- Firategrast Integrin alpha-4/beta-1 antagonist
- Natalizumab Integrin alpha-4/beta-7 inhibitor
- UCB-1184197 Integrin alpha-4 inhibitor
- Vedolizumab Integrin alpha-4/beta-7 inhibitor